



Bayer AG
Communications
51368 Leverkusen
Germany
Tel. +49 214 30-1
media.bayer.com

News Release

Solidarity in the fight against COVID-19:

Bayer to donate EUR 1 million to support the fight against the coronavirus pandemic in France

- Money will help caregivers, patients and their families, and fund research
- Bayer is supporting various further initiatives in France

Leverkusen, April 17, 2020 – Bayer will donate EUR 1 million to the “All united against the virus” alliance set up by the Fondation de France, the Assistance Publique – Hôpitaux de Paris (AP-HP) hospital network and the Pasteur Institute.

The money will enable the alliance to provide psychological support for caregivers, patients and their families as well as to improve the patient care pathway. It will also be used to fund research projects to better understand the coronavirus and the ongoing pandemic, and to develop antibody detection tests, effective treatments and vaccines.

“As a player in the health sector, we are particularly sensitive to this unprecedented crisis and are doing everything in our power to support the fight against COVID-19. We salute the exceptional work carried out by hospital staff and all the caregivers who fight daily against the epidemic,” said Benoît Rabilloud, Senior Bayer Representative in France. “Our support for the ‘All united against the virus’ alliance reflects our corporate responsibility and our solidarity with French society.”

“In light of the many challenges we face today and will continue to face in the months to come, there is a growing conviction that never in our modern history have we needed mutual help and solidarity so much,” stressed Axelle Davezac, Director General of the Fondation de France.

In addition to the support provided to the “All united against the virus” alliance, Bayer is promoting various further initiatives to fight the coronavirus pandemic in France. The company is supporting a study conducted by medical experts to assess the effectiveness of a novel combination of molecules for the treatment of COVID-19 patients. In addition, it is making its expertise available to validate a new and faster method of test screening. Bayer has already donated protective equipment (including more than 12,000 face masks), dermatological products and also meals in the Lyon region.

Bayer is supporting the worldwide fight against the corona pandemic with its products, technical equipment, know-how and the engagement of its employees. You can find a current overview here: <https://www.bayer.com/en/coronavirus-covid-19-update.aspx>.

A digital press kit is available at:

<https://www.media.bayer.com/baynews/baynews.nsf/id/presskit-corona>

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Note to the editors:

More information about the “All united against the virus” alliance can be found at:

<https://www.fondationdefrance.org/fr/tous-unis-contre-le-virus-la-fondation-de-france-lap-hp-et-linstitut-pasteur-lancet-un-appel-la>

Contact:

Dirk Frenzel: +49 175 29908

Email: dirk.frenzel@bayer.com

For more information go to www.bayer.com.

Follow us on Twitter: twitter.com/Bayer

df (2020-0120E)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.